Patents by Inventor Michael Bardroff
Michael Bardroff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230302155Abstract: Aspects of this disclosure relate generally to the use of biomaterials for the in vivo generation of CAR expressing cells. In some embodiments, the biomaterials comprise one or more of a cell recruitment composition, a viral vector, and/or a cell activation agent.Type: ApplicationFiled: August 20, 2021Publication date: September 28, 2023Inventors: Sandeep Tharian Koshy, Glenn Dranoff, Maria Anna Sofia Broggi, Chris Bridgeman, Stephen Michael Canham, Yoel Melles, Regis Cebe, Brian Walter Granda, Louise Mary Treanor, Shyamali Jayashankar, Jennifer Yang, Amy Rayo, Andrew Patrick Price, Darko Skegro, Justine Guyot, Tushar Dattu Apsunde, Cameron Chuck-munn Lee, Michael Bardroff, Sandra Miller
-
Publication number: 20230256017Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.Type: ApplicationFiled: February 26, 2021Publication date: August 17, 2023Inventors: Jennifer BROGDON, Glenn DRANOFF, Michael R. GREENE, Anniesha HACK, Olja KODRASI, Elizabeth Dorothy PRATICO, Andrew PRICE, Andrew Marc STEIN, Amy RAYO, Jennifer YANG, Brian Walter GRANDA, Attilio BONDANZA, Boris ENGELS, Hyungwook LIM, Akash SOHONI, Louise TREANOR, Xu ZHU, Carla GUIMARAES, Shyamali JAYASHANKAR, Sandeep Tharian KOSHY, Regis CEBE, Michael BARDROFF, Sandra MILLER
-
Patent number: 9296813Abstract: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.Type: GrantFiled: February 12, 2014Date of Patent: March 29, 2016Assignee: NOVARTIS AGInventors: Janine R. Shulok, Feng Cong, Mark C. Fishman, Seth Ettenberg, Michael Bardroff, Mariel Donzeau, Stefanie Urlinger
-
Publication number: 20140341901Abstract: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.Type: ApplicationFiled: January 24, 2014Publication date: November 20, 2014Applicant: NOVARTIS AGInventors: Janine R. SHULOK, Feng CONG, Mark C. FISHMAN, Seth ETTENBERG, Michael BARDROFF, Mariel DONZEAU, Stefanie URLINGER
-
Publication number: 20140170147Abstract: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.Type: ApplicationFiled: February 12, 2014Publication date: June 19, 2014Applicant: NOVARTIS AGInventors: Janine R. SHULOK, Feng CONG, Mark C. FISHMAN, Seth ETTENBERG, Michael BARDROFF, Mariel DONZEAU, Stefanie URLINGER
-
Patent number: 8715657Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: GrantFiled: March 29, 2010Date of Patent: May 6, 2014Assignee: Novartis AGInventors: Michael Bardroff, Jose M. Carballido Herrera, Daniela Della Ducata, Christoph Heusser, Ute Jaeger, Christoph Schwaerzler
-
Patent number: 8673306Abstract: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.Type: GrantFiled: January 12, 2007Date of Patent: March 18, 2014Assignee: Novartis AGInventors: Janine Shulok, Feng Cong, Mark Fishman, Seth Ettenberg, Michael Bardroff, Mariel Donzeau, Stefanie Urlinger
-
Publication number: 20130323237Abstract: The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: ApplicationFiled: March 15, 2013Publication date: December 5, 2013Inventors: Michael BARDROFF, Matthew EDWARDS, Mehmet TUR, Olaf RATSCH
-
Patent number: 8420787Abstract: The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis inflammatory bowel disease, and Hodgkin's lymphoma.Type: GrantFiled: February 21, 2007Date of Patent: April 16, 2013Assignee: Novartis AGInventors: Michael Bardroff, Matthew Edwards, Mehmet Kemal Tur, Olaf Ratsch
-
Patent number: 8329886Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: GrantFiled: May 16, 2012Date of Patent: December 11, 2012Assignees: Hoffman-La Roche Inc., Morphosys AGInventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Publication number: 20120225478Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: ApplicationFiled: May 16, 2012Publication date: September 6, 2012Inventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Patent number: 8216577Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: GrantFiled: July 28, 2009Date of Patent: July 10, 2012Assignees: F. Hoffmann-La Roche AG, MorphoSys AGInventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Patent number: 8114964Abstract: The present invention relates to at least one novel anti-MCP-1 antibody, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: November 19, 2007Date of Patent: February 14, 2012Assignee: Centocor, Inc.Inventors: Anuk Das, Raymond Sweet, Ping Tsui, Michael Bardroff
-
Publication number: 20120034231Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: ApplicationFiled: March 29, 2010Publication date: February 9, 2012Applicant: NOVARTIS AGInventors: Michael Bardroff, José M. Carballido Herrera, Daniela Della Ducata, Christoph Heusser, Ute Jaeger, Christoph Schwaerzler
-
Publication number: 20120023600Abstract: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.Type: ApplicationFiled: January 12, 2007Publication date: January 26, 2012Inventors: Janine Shulok, Feng Cong, Mark Fishman, Seth Ettenberg, Michael Bardroff, Mariel Donzeau, Stefanie Urlinger
-
Patent number: 7794719Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the R-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: GrantFiled: February 20, 2003Date of Patent: September 14, 2010Assignees: F. Hoffmann-La Roche AG, Morphosys AGInventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Publication number: 20100172907Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: ApplicationFiled: July 28, 2009Publication date: July 8, 2010Inventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus kretzschmar, Hansruedi Loetscher, Corinna Lohning, Christer Nordstedt, Christine Rothe
-
Publication number: 20090186022Abstract: The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis inflammatory bowel disease, and Hodgkin's lymphoma.Type: ApplicationFiled: February 21, 2007Publication date: July 23, 2009Inventors: Michael Bardroff, Matthew Edwards, Mehmet Tur, Olaf Ratsch
-
Publication number: 20090068109Abstract: The present invention relates to at least one novel anti-MCP-1 antibody, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: November 19, 2007Publication date: March 12, 2009Inventors: Anuk Das, Raymond Sweet, Ping Tsui, Michael Bardroff
-
Publication number: 20050169925Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the R-A4 peptide, wherein the first region comprises the amino acid sequence ABFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: ApplicationFiled: February 20, 2003Publication date: August 4, 2005Inventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Lohning, Christer Nordstedt, Christine Rothe